Drug intelligence / Profile preview

RioDerm-003

Development stage: Unknown
Lead developer: RION
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

RioDerm-003 is an investigational biologic therapy under development for the treatment of radiation dermatitis (radiodermatitis). The drug consists of exosomes containing a platelet exosome product (PEP) formulated with a carbomer carrier, delivered as a powder. It is based on next-generation platelet-derived exosome technology designed to harness the regenerative and therapeutic properties of exosomes for skin healing. The developer, Rion, is focused on advancing exosome-based therapies for various indications in regenerative medicine[1][2][3].

Beyond the preview

Go deeper on RioDerm-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RioDerm-003.

Explore the full profile